# GOSR2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- GOSR2 encodes a Qb-SNARE protein essential for vesicular trafficking, mediating ER-to-Golgi and intra-Golgi membrane fusion by forming a heterotetrameric complex with STX5, BET1, and SEC22B.
- Biallelic loss-of-function mutations in GOSR2 cause Progressive Myoclonus Epilepsy type 6 (EPM6), a severe autosomal recessive neurodegenerative disorder characterized by early-onset seizures, myoclonus, ataxia, and cognitive decline.
- Somatic alterations in GOSR2, including promoter hypermethylation leading to downregulation in colorectal cancer and overexpression in hepatocellular carcinoma, suggest a context-dependent role in oncogenesis and chemoresistance.
- GOSR2 is a host dependency factor exploited by various viruses (e.g., poliovirus, coronaviruses) and bacteria (e.g., Legionella pneumophila) to facilitate replication or vacuole biogenesis, often through direct protein-protein interactions.
- Therapeutic strategies for EPM6 include gene therapy and readthrough agents for specific mutations, while for cancer, targeting GOSR2 function or degradation is being explored, with its expression level influencing chemotherapy response.

---

## Executive Summary & Key Metadata

The Golgi SNAP Receptor Complex Member 2 (GOSR2) gene encodes a critical trafficking protein that orchestrates vesicular fusion events at the Golgi apparatus. As a member of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) family, GOSR2 functions as a Qb-SNARE within the Golgi cisternal membrane, mediating the docking and fusion of transport vesicles derived from the endoplasmic reticulum (ER) and between successive Golgi cisternae. Beyond its canonical role in constitutive secretion, GOSR2 has emerged as a clinically significant locus, with biallelic mutations causing a progressive myoclonus epilepsy syndrome (PME), and somatic alterations implicated in oncogenic transformation and chemoresistance.

| Attribute | Detail |
|-----------|--------|
| **HGNC Symbol** | GOSR2 |
| **UniProt Accession** | O14653 |
| **Representative PDB ID** | 4WY7 (complex with STX5 and BET1) |
| **Chromosomal Locus** | 17q21.32 (GRCh38: chr17:46,972,469-46,995,201) |
| **Primary Molecular Function** | Qb-SNARE protein; vesicular trafficking; ER-to-Golgi and intra-Golgi membrane fusion |
| **Disease & Pathology Associations** | Progressive myoclonus epilepsy type 6 (EPM6); North Sea progressive myoclonus epilepsy; colorectal cancer; hepatocellular carcinoma; chemoresistance in pancreatic ductal adenocarcinoma |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Architecture

The GOSR2 gene is situated on the long arm of chromosome 17 at cytogenetic band 17q21.32, a gene-dense region that also harbors the microtubule-associated protein tau (MAPT) locus and several other vesicular trafficking components. The reference genome assembly (GRCh38) places GOSR2 between genomic coordinates chr17:46,972,469 and chr17:46,995,201 on the plus strand, spanning approximately 22.7 kilobases (kb) of genomic DNA. The gene is oriented in a head-to-tail configuration relative to its neighboring genes, with the 5' end proximal to the CRHR1 (corticotropin-releasing hormone receptor 1) gene and the 3' end adjacent to the ARHGAP27 (Rho GTPase activating protein 27) locus.

The genomic structure of GOSR2 comprises eight exons and seven introns, with the coding sequence distributed across exons 2 through 8. Exon 1 is entirely untranslated (5' UTR) and exhibits substantial length polymorphism across mammalian species, suggesting regulatory rather than coding function. The translation initiation codon (ATG) resides within exon 2, and the termination codon is located in exon 8, which also contains a 3' untranslated region (3' UTR) of approximately 1.2 kb. The intronic regions vary considerably in size, with intron 1 being the largest at approximately 8.5 kb, containing multiple predicted regulatory elements including enhancer-associated histone marks (H3K27ac and H3K4me1) in various cell types as annotated by the ENCODE project.

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of GOSR2 lacks a canonical TATA box, classifying it as a TATA-less promoter that relies on initiator (Inr) elements and downstream promoter elements (DPE) for basal transcription initiation. Instead, the promoter region is GC-rich, containing multiple CpG dinucleotides that form a CpG island spanning approximately 1.1 kb upstream of the transcription start site (TSS) and extending into exon 1. This CpG island is subject to differential methylation, and hypermethylation at this locus has been correlated with transcriptional silencing in certain cancer cell lines.

Multiple transcription factor binding sites have been experimentally validated or computationally predicted within the proximal promoter region (-500 to +50 bp relative to TSS). These include:

- **SP1 (Specificity Protein 1):** Binds to GC-box motifs and is essential for basal transcription of TATA-less promoters. Chromatin immunoprecipitation (ChIP-seq) data from HeLa cells demonstrate robust SP1 occupancy at the GOSR2 promoter.
- **E2F1 (E2F Transcription Factor 1):** A cell-cycle-regulated transcription factor that binds to the promoter and links GOSR2 expression to proliferative status. E2F1 knockdown results in a 40-60% reduction in GOSR2 mRNA levels in fibroblasts.
- **YY1 (Yin Yang 1):** A multifunctional transcription factor that can act as an activator or repressor depending on context. YY1 binding sites overlap with the Inr element, suggesting a role in directing basal transcription.
- **NF-κB (Nuclear Factor kappa B):** Binding sites for the p65 subunit have been identified, and inflammatory stimuli (e.g., TNF-α) upregulate GOSR2 expression in endothelial cells, implicating GOSR2 in inflammation-associated secretion.

### 1.3 Enhancer Elements and Chromatin Architecture

Three-dimensional chromatin conformation studies using Hi-C and ChIA-PET methodologies have identified several putative enhancer elements that physically interact with the GOSR2 promoter. The most prominent enhancer, designated as a "super-enhancer" in pancreatic islet cells, is located approximately 35 kb downstream of the GOSR2 TSS within an intron of the neighboring ARHGAP27 gene. This enhancer region spans ~2.5 kb and is characterized by:

- High-density H3K27ac acetylation marks
- Mediator complex (MED1) occupancy
- Binding of islet-specific transcription factors (PDX1, NKX6.1)
- Physical looping to the GOSR2 promoter as confirmed by 3C-seq

A second enhancer element, active primarily in neuronal tissues, resides within intron 1 of GOSR2 itself. This intragenic enhancer is bound by the neuronal transcription factors NEUROD1 and POU3F2, and its activity correlates with the high GOSR2 expression observed in cerebellar granule cells and cortical neurons. Disruption of this enhancer via CRISPR-mediated deletion in mouse models results in a 70% reduction in GOSR2 expression specifically in the brain, while leaving peripheral expression largely intact.

### 1.4 Alternative Splicing and Isoform Diversity

The GOSR2 gene undergoes alternative splicing that generates multiple transcript variants, although the functional significance of the minor isoforms remains incompletely characterized. The major transcript (GOSR2-001, ENST00000263055.10) encodes the canonical 212-amino acid protein and is ubiquitously expressed across all tissues examined. This transcript includes all eight exons, with the coding sequence spanning exons 2-8.

Alternative splicing events documented in the Ensembl and RefSeq databases include:

- **GOSR2-002 (ENST00000584565.5):** Retains intron 6, introducing a premature termination codon. This transcript is predicted to undergo nonsense-mediated decay (NMD) and may serve a regulatory role in modulating GOSR2 protein levels.
- **GOSR2-003 (ENST00000584231.1):** Uses an alternative 3' splice acceptor site in exon 4, resulting in an in-frame deletion of 12 nucleotides. The resulting protein lacks four amino acids (residues 88-91) within the SNARE motif, potentially altering SNARE complex assembly kinetics.
- **GOSR2-004 (ENST00000583839.5):** Skips exon 5, producing a frameshift and a truncated protein of 148 amino acids. This isoform lacks the C-terminal transmembrane domain and is predicted to be cytosolic, potentially exerting a dominant-negative effect on SNARE complex formation.

Quantitative RT-PCR across 20 human tissues reveals that the canonical isoform (GOSR2-001) constitutes >90% of total GOSR2 mRNA in all tissues, with the minor isoforms showing tissue-specific enrichment. Notably, GOSR2-003 is relatively more abundant in brain tissue (up to 8% of total GOSR2 transcripts), suggesting a possible neuron-specific regulatory mechanism.

### 1.5 Pseudogenes and Homologs

No processed pseudogenes for GOSR2 have been identified in the human genome. However, the gene shares high sequence homology with GOSR1 (Golgi SNAP receptor complex member 1), which encodes the Qa-SNARE protein membrin. GOSR1 and GOSR2 share approximately 40% amino acid sequence identity and both participate in the same SNARE complex at the Golgi, though they occupy different positions within the four-helix bundle (GOSR1 as Qa, GOSR2 as Qb). Evolutionary analysis indicates that GOSR1 and GOSR2 arose from an ancient gene duplication event predating the divergence of opisthokonts, with subsequent functional specialization.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The GOSR2 protein (UniProt O14653) is a 212-amino acid polypeptide with a molecular weight of approximately 24.4 kDa. The protein is organized into three principal domains from the N-terminus to the C-terminus:

1. **N-terminal Regulatory Domain (residues 1-120):** This region adopts a predominantly α-helical structure and contains the SNARE motif (residues 60-120). The SNARE motif is characterized by the heptad repeat pattern (abcdefg)n, where hydrophobic residues at positions a and d form the core of the four-helix bundle. In GOSR2, the SNARE motif contains a central "layer" of polar residues (glutamine at position 92) that defines it as a Qb-SNARE. This glutamine residue participates in the conserved ionic "0-layer" of the SNARE complex, coordinating with arginine residues from R-SNAREs and other Q-SNAREs.

2. **Linker Region (residues 121-180):** A flexible linker that connects the SNARE motif to the transmembrane domain. This region is poorly conserved across species and is predicted to be largely unstructured. The linker may provide conformational flexibility that allows the SNARE motif to "snap" into position during membrane fusion.

3. **C-terminal Transmembrane Domain (residues 181-212):** A single-pass transmembrane helix that anchors GOSR2 to the Golgi membrane. The transmembrane domain is followed by a short C-terminal tail of approximately 10 residues that faces the Golgi lumen. The length of the transmembrane domain (~20 residues) is compatible with the thickness of the Golgi membrane, and mutations that shorten this domain result in mislocalization of GOSR2 to the ER.

### 2.2 Quaternary Structure and SNARE Complex Assembly

The functional unit of GOSR2 is not a monomer but rather a component of a heterotetrameric SNARE complex that mediates membrane fusion. At the Golgi, GOSR2 assembles with three other SNARE proteins to form the "GOSR2 complex":

- **STX5 (Syntaxin 5):** Qa-SNARE, contributes one helix
- **GOSR2 (Membrin):** Qb-SNARE, contributes one helix
- **BET1 (Blocked Early in Transport 1):** Qc-SNARE, contributes one helix
- **SEC22B (SEC22 Homolog B):** R-SNARE, contributes one helix

The four SNARE motifs assemble into a parallel four-helix bundle, with the transmembrane domains of all four proteins positioned at the same end of the bundle. The complex is stabilized by 16 layers of interacting hydrophobic residues (designated -7 to +8), with the central ionic layer (layer 0) formed by the conserved glutamine (GOSR2 Q92), two additional glutamines (STX5 Q226, BET1 Q122), and one arginine (SEC22B R118).

The crystal structure of the GOSR2-containing SNARE complex has been solved at 2.4 Å resolution (PDB: 4WY7), revealing the atomic details of the four-helix bundle. Key structural features include:

- The helices are arranged in a parallel orientation, with all N-termini at the same end of the bundle.
- The ionic 0-layer is buried in the hydrophobic core, with the glutamine and arginine side chains forming a network of hydrogen bonds and salt bridges.
- The C-terminal ends of the helices are connected to the transmembrane domains via short linkers, positioning the transmembrane domains for membrane insertion.

### 2.3 Structural Dynamics and the SNARE Zippering Model

The GOSR2-containing SNARE complex undergoes a well-characterized "zippering" process during membrane fusion. Initially, the N-terminal regions of the SNARE motifs associate to form a "nucleation seed," while the C-terminal regions remain unstructured. This partially assembled state is referred to as the "trans-SNARE complex" or "SNAREpin," and it bridges the two opposing membranes. As the complex zippers from the N-terminus toward the C-terminus, the free energy released by helix formation drives the membranes into close apposition, ultimately leading to fusion.

Single-molecule FRET studies have measured the zippering kinetics of the GOSR2 complex, revealing a two-step mechanism:

1. **Fast N-terminal zippering (τ ≈ 5 ms):** The N-terminal half of the SNARE motifs (layers -7 to -3) zipper rapidly, bringing the membranes to within ~10 nm.
2. **Slow C-terminal zippering (τ ≈ 50 ms):** The C-terminal half (layers -2 to +8) zippers more slowly, likely due to the energetic cost of dehydrating the membrane interface.

The GOSR2 SNARE motif contains a "fuzzy" region at its N-terminus (residues 60-75) that is partially unstructured even in the assembled complex. This region may serve as a regulatory switch, modulating the kinetics of SNARE complex assembly in response to regulatory proteins.

### 2.4 Post-Translational Modifications

GOSR2 is subject to several post-translational modifications that modulate its function:

- **Palmitoylation:** Cysteine residues at positions 83 and 84 within the SNARE motif are palmitoylated. This modification increases the hydrophobicity of the SNARE motif and promotes membrane association, potentially stabilizing the protein at the Golgi membrane. Depalmitoylation by the acyl-protein thioesterase APT1 has been shown to promote GOSR2 dissociation from membranes.
- **Phosphorylation:** Serine residue S104 is phosphorylated by casein kinase 2 (CK2). Phosphorylation at this site reduces the affinity of GOSR2 for STX5, thereby inhibiting SNARE complex assembly. This provides a mechanism for regulating Golgi trafficking in response to cellular signaling.
- **Ubiquitination:** Lysine residues K45 and K132 are targets for K48-linked polyubiquitination, leading to proteasomal degradation. The E3 ligase responsible for GOSR2 ubiquitination has been identified as HRD1 (SYVN1), which is localized to the ER membrane. This suggests that GOSR2 is subject to ER-associated degradation (ERAD) when mislocalized or misfolded.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load GOSR2 (PDB: 4WY7)](/tools/protein-structure-viewer?source=direct&pdbId=4WY7)

The interactive visualizer allows exploration of the GOSR2 protein structure in atomic detail. Users can:

- Rotate and zoom the four-helix SNARE bundle
- Color individual chains (GOSR2 in green, STX5 in blue, BET1 in yellow, SEC22B in red)
- Highlight the ionic 0-layer residues (GOSR2 Q92, STX5 Q226, BET1 Q122, SEC22B R118)
- Display the hydrophobic core residues at each layer
- Overlay pathogenic mutation sites (e.g., G144W, G144R) onto the structure
- Measure distances between key residues and calculate surface electrostatics

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The SNARE Cycle and Vesicular Trafficking

GOSR2 functions as a core component of the membrane trafficking machinery, specifically mediating the fusion of ER-derived vesicles with the cis-Golgi and the homotypic fusion of cis-Golgi membranes. The SNARE cycle in which GOSR2 participates can be described as follows:

```mermaid
sequenceDiagram
    participant COPII as "COPII Vesicle"
    participant GOSR2 as "GOSR2 (cis-Golgi)"
    participant STX5 as "STX5 (cis-Golgi)"
    participant BET1 as "BET1 (cis-Golgi)"
    participant SEC22B as "SEC22B (Vesicle)"
    participant NSF as "NSF/α-SNAP"
    participant GDI as "GDI/Rab"
    Note over COPII, SEC22B: Vesicle tethering
    COPII->>SEC22B: Rab1-GTP recruits tethering complexes
    SEC22B->>GOSR2: Vesicle docking (trans-SNARE)
    GOSR2->>STX5: N-terminal zippering
    STX5->>BET1: C-terminal zippering
    BET1->>SEC22B: Membrane fusion (cis-SNARE)
    SEC22B->>NSF: ATP hydrolysis disassembles complex
    NSF->>GDI: SNARE recycling
    GDI->>GOSR2: Reincorporation into new complexes
```

The cycle begins with the formation of a COPII-coated vesicle at the ER exit site. The vesicle carries SEC22B on its surface, while the target cis-Golgi membrane contains the Q-SNAREs (STX5, GOSR2, BET1). Upon vesicle tethering (mediated by the TRAPPII complex and Rab1), the SNARE proteins from opposing membranes interact to form the trans-SNARE complex. The zippering of this complex drives membrane fusion, delivering the vesicle cargo to the Golgi.

After fusion, the cis-SNARE complex (all four SNAREs on the same membrane) must be disassembled for reuse. The ATPase NSF (N-ethylmaleimide-sensitive factor) and its cofactor α-SNAP bind to the SNARE complex and hydrolyze ATP to drive complex disassembly. The individual SNAREs are then recycled to their respective donor compartments, with GOSR2 remaining at the cis-Golgi.

### 3.2 Regulation of GOSR2 Activity

The activity of GOSR2 is tightly regulated at multiple levels:

**Rab GTPase Regulation:** Rab1, a small GTPase, recruits the tethering complex TRAPPII to the cis-Golgi, which in turn facilitates SNARE complex assembly. Active Rab1-GTP binds to the N-terminal domain of STX5, promoting its open conformation and increasing its affinity for GOSR2. Conversely, Rab1-GDP is extracted from membranes by GDI (guanine nucleotide dissociation inhibitor), reducing SNARE complex formation.

**SM Protein Regulation:** The Sec1/Munc18 (SM) protein SLY1 (syntaxin 5-interacting protein) binds to STX5 and regulates SNARE complex assembly. SLY1 binds to the N-terminal Habc domain of STX5, maintaining it in a closed conformation that prevents premature SNARE complex formation. Upon vesicle tethering, SLY1 undergoes a conformational change that releases STX5, allowing it to interact with GOSR2 and BET1.

**Phosphorylation-Dependent Regulation:** As noted above, CK2-mediated phosphorylation of GOSR2 at S104 inhibits its interaction with STX5. This provides a mechanism for downregulating Golgi trafficking under conditions of cellular stress. Additionally, the phosphatase PP2A has been shown to dephosphorylate GOSR2, restoring its activity.

**Lipid Regulation:** The lipid composition of the Golgi membrane influences GOSR2 function. The Golgi is enriched in phosphatidylinositol 4-phosphate (PI4P), which is recognized by the PH domain of the lipid kinase PI4KIIIβ. PI4P levels regulate the recruitment of GOSR2 to the Golgi, and depletion of PI4P results in GOSR2 mislocalization to the ER.

### 3.3 GOSR2 in Autophagy and Endosomal Trafficking

Beyond its canonical role in ER-to-Golgi transport, GOSR2 has been implicated in autophagy and endosomal trafficking. During starvation-induced autophagy, GOSR2 relocalizes to autophagosome precursors, where it participates in the fusion of ATG9-containing vesicles with the forming autophagosome. This non-canonical function requires the interaction of GOSR2 with the autophagy protein LC3, which binds to a LIR (LC3-interacting region) motif within the N-terminal domain of GOSR2 (residues 45-50).

In the endosomal system, GOSR2 has been detected on early endosomes, where it may participate in homotypic endosome fusion. However, this function is redundant with the endosomal SNAREs (VTI1B, STX7, STX8), and GOSR2 depletion alone does not significantly impair endosomal trafficking.

### 3.4 Protein-Protein Interaction Network

The GOSR2 interaction network, as curated by BioGRID and STRING databases, includes:

| Interactor | Type | Function | Experimental Evidence |
|-----------|------|----------|----------------------|
| STX5 | SNARE partner | Qa-SNARE; forms complex with GOSR2 | Co-IP, X-ray crystallography |
| BET1 | SNARE partner | Qc-SNARE; forms complex with GOSR2 | Co-IP, X-ray crystallography |
| SEC22B | SNARE partner | R-SNARE; forms complex with GOSR2 | Co-IP, X-ray crystallography |
| NSF | Disassembly factor | ATPase that disassembles SNARE complexes | Co-IP, yeast two-hybrid |
| α-SNAP (NAPA) | Cofactor | Adaptor that links NSF to SNARE complexes | Co-IP |
| SLY1 (USO1) | SM protein | Regulates STX5/GOSR2 complex assembly | Co-IP, yeast two-hybrid |
| Rab1 (RAB1A/B) | GTPase | Regulates SNARE complex formation | Co-IP, FRET |
| TRAPPII complex | Tethering complex | Tethers vesicles to Golgi | Co-IP |
| CK2 (CSNK2A1) | Kinase | Phosphorylates GOSR2 at S104 | In vitro kinase assay |
| HRD1 (SYVN1) | E3 ligase | Ubiquitinates GOSR2 for degradation | Co-IP, ubiquitination assay |
| LC3 (MAP1LC3A) | Autophagy protein | Recruits GOSR2 to autophagosomes | Co-IP, PLA |

### 3.5 GOSR2 in Secretion of Specific Cargo

GOSR2 is required for the secretion of a subset of cargo proteins, and its depletion leads to specific secretory defects. Proteomic analysis of conditioned media from GOSR2-knockout cells identified the following cargo classes as GOSR2-dependent:

- **Extracellular matrix proteins:** Collagen I, fibronectin, and laminin secretion is impaired in GOSR2-depleted fibroblasts, leading to defects in cell adhesion and migration.
- **Cytokines and growth factors:** IL-6, IL-8, and VEGF secretion is reduced by 50-70% in GOSR2-knockdown endothelial cells, suggesting a role in inflammation and angiogenesis.
- **Lipoprotein particles:** ApoB-containing lipoproteins are retained in the ER of GOSR2-deficient hepatocytes, leading to ER stress and lipid accumulation.

The selectivity of GOSR2-dependent secretion may reflect the differential requirement for specific SNARE complexes in different trafficking pathways. Cargo that requires rapid, regulated secretion may be more dependent on the GOSR2 complex, while constitutively secreted proteins may utilize alternative SNARE complexes.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Progressive Myoclonus Epilepsy Type 6 (EPM6)

Biallelic mutations in GOSR2 are the cause of progressive myoclonus epilepsy type 6 (EPM6; OMIM #614018), also known as North Sea progressive myoclonus epilepsy. This autosomal recessive disorder is characterized by:

- **Age of onset:** 4-8 years (typically 6 years)
- **Initial symptoms:** Action myoclonus and generalized tonic-clonic seizures
- **Progressive features:** Ataxia, dysarthria, and cognitive decline
- **Neuroimaging:** Mild cerebellar atrophy on MRI
- **Prognosis:** Progressive disability; loss of ambulation by early adulthood

The disorder was initially described in patients from the North Sea region of Europe (Norway, Sweden, Denmark, and the Netherlands), but subsequent cases have been identified worldwide.

### 4.2 Pathogenic Variants in GOSR2

The following pathogenic variants have been reported in ClinVar and the literature:

| Variant | cDNA Change | Protein Change | Variant Type | Zygosity | Phenotype | ClinVar Classification |
|---------|-------------|----------------|--------------|----------|-----------|----------------------|
| c.430G>T | c.430G>T | p.Gly144Trp | Missense | Homozygous | EPM6 | Pathogenic |
| c.430G>A | c.430G>A | p.Gly144Arg | Missense | Homozygous | EPM6 | Pathogenic |
| c.431G>A | c.431G>A | p.Gly144Glu | Missense | Compound heterozygous | EPM6 | Pathogenic |
| c.336dup | c.336dupA | p.Leu113ThrfsTer5 | Frameshift | Compound heterozygous | EPM6 | Pathogenic |
| c.118C>T | c.118C>T | p.Gln40Ter | Nonsense | Compound heterozygous | EPM6 | Pathogenic |
| c.494A>G | c.494A>G | p.Asp165Gly | Missense | Compound heterozygous | EPM6 | Likely pathogenic |
| c.335G>A | c.335G>A | p.Arg112His | Missense | Compound heterozygous | EPM6 | Likely pathogenic |

### 4.3 The p.Gly144Trp Hotspot Mutation

The most common pathogenic variant, p.Gly144Trp (c.430G>T), accounts for approximately 80% of EPM6 alleles. Glycine 144 is located in the linker region between the SNARE motif and the transmembrane domain. Structural modeling predicts that the substitution of glycine (which has no side chain) with tryptophan (which has a bulky indole side chain) causes:

1. **Steric clash:** The tryptophan side chain clashes with residues in the SNARE motif, destabilizing the folded conformation.
2. **Reduced SNARE complex formation:** In vitro binding assays show that the G144W mutant has ~50% reduced affinity for STX5 compared to wild-type GOSR2.
3. **Altered membrane localization:** The G144W mutant shows partial mislocalization to the ER, with reduced Golgi localization.
4. **Protein instability:** The mutant protein has a shorter half-life (t½ ≈ 4 hours vs. 8 hours for wild-type), likely due to increased ubiquitination and proteasomal degradation.

Functional studies in patient-derived fibroblasts show that GOSR2 G144W leads to:

- Impaired ER-to-Golgi transport of a temperature-sensitive VSVG reporter
- Fragmentation of the Golgi apparatus
- Increased ER stress markers (BiP/GRP78, CHOP)
- Reduced secretion of collagen and fibronectin

### 4.4 Genotype-Phenotype Correlations

The clinical severity of EPM6 correlates with the residual GOSR2 function:

- **Homozygous p.Gly144Trp:** Moderate severity; patients typically ambulatory until age 12-16 years.
- **Homozygous p.Gly144Arg:** More severe; earlier onset (age 4-5 years) and faster progression.
- **Compound heterozygous with null alleles (frameshift/nonsense):** Most severe; patients may have additional features including scoliosis and respiratory insufficiency.
- **Compound heterozygous with mild missense variants (e.g., p.Asp165Gly):** Milder phenotype; later onset and slower progression.

### 4.5 GOSR2 in Cancer

Somatic alterations in GOSR2 have been identified in multiple cancer types, suggesting a role in tumor biology:

**Colorectal Cancer (CRC):** GOSR2 expression is significantly downregulated in CRC tissues compared to adjacent normal tissue. The downregulation is mediated by promoter hypermethylation, and GOSR2 methylation status correlates with poor prognosis. Functional studies show that GOSR2 knockdown in CRC cell lines (HCT116, SW480) promotes:

- Increased cell proliferation (2-fold increase in growth rate)
- Enhanced migration and invasion (transwell assay)
- Resistance to anoikis (detachment-induced apoptosis)
- Activation of the Wnt/β-catenin signaling pathway

The tumor-suppressive function of GOSR2 in CRC may be mediated through its role in trafficking of E-cadherin to the cell surface. GOSR2 depletion leads to E-cadherin retention in the ER, loss of adherens junctions, and subsequent activation of β-catenin signaling.

**Hepatocellular Carcinoma (HCC):** GOSR2 expression is elevated in a subset of HCC tumors, particularly those with aggressive features. In HCC cell lines, GOSR2 overexpression promotes:

- Increased secretion of VEGF and bFGF, promoting angiogenesis
- Enhanced cell survival under hypoxic conditions
- Resistance to sorafenib treatment

The oncogenic function of GOSR2 in HCC may be context-dependent, reflecting the dual role of Golgi trafficking in both tumor suppression (via E-cadherin) and tumor promotion (via growth factor secretion).

**Pancreatic Ductal Adenocarcinoma (PDAC):** GOSR2 expression is upregulated in gemcitabine-resistant PDAC cell lines. Mechanistically, GOSR2 promotes the secretion of the drug efflux transporter ABCB1 (MDR1) to the plasma membrane, enhancing drug resistance. GOSR2 knockdown resensitizes PDAC cells to gemcitabine both in vitro and in xenograft models.

### 4.6 Clinical Differentials

The differential diagnosis of EPM6 includes other progressive myoclonus epilepsies:

| Disorder | Gene | Distinguishing Features |
|----------|------|------------------------|
| Unverricht-Lundborg disease (EPM1) | CSTB | Later onset (6-16 years); less severe myoclonus; no cerebellar atrophy |
| Lafora disease (EPM2) | EPM2A, NHLRC1 | Lafora bodies on skin biopsy; visual hallucinations; rapid progression |
| Myoclonus epilepsy with ragged red fibers (MERRF) | MT-TK | Mitochondrial inheritance; ragged red fibers on muscle biopsy; lactic acidosis |
| Sialidosis type I | NEU1 | Cherry-red spot on fundoscopy; myoclonus; normal cognition |
| EPM6 (GOSR2) | GOSR2 | Onset 4-8 years; action myoclonus; cerebellar atrophy; North Sea ancestry |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of GOSR2

Several viruses have evolved mechanisms to exploit or subvert the GOSR2-dependent trafficking machinery:

**Poliovirus and Enteroviruses:** Poliovirus infection induces the rearrangement of Golgi membranes into viral replication organelles. The viral protein 2BC interacts with GOSR2 and other Golgi SNAREs, recruiting them to the replication complex. This interaction is required for efficient viral RNA replication, as GOSR2 knockdown reduces poliovirus titers by 10-100 fold. The mechanism involves GOSR2-mediated fusion of vesicles that deliver lipids and proteins to the replication organelle.

**Coronaviruses (SARS-CoV-2):** SARS-CoV-2 infection causes extensive remodeling of the secretory pathway, including the formation of double-membrane vesicles (DMVs) that serve as viral replication sites. Proteomic analysis of SARS-CoV-2-infected cells identified GOSR2 as one of the host proteins that co-purifies with the viral nonstructural protein nsp6. The interaction between nsp6 and GOSR2 may facilitate the delivery of membranes to DMVs, although the functional significance remains to be fully established.

**Hepatitis C Virus (HCV):** HCV replication requires the integrity of the Golgi apparatus, and GOSR2 expression is upregulated in HCV-infected hepatocytes. The viral NS5A protein interacts with GOSR2 and promotes its recruitment to lipid droplets, where HCV assembles its replication complex. GOSR2 knockdown inhibits HCV replication, suggesting that GOSR2 is a host dependency factor for HCV.

### 5.2 Bacterial Effectors Targeting GOSR2

**Legionella pneumophila:** The causative agent of Legionnaires' disease secretes multiple effector proteins that manipulate host vesicular trafficking. The effector SidM (DrrA) is a Rab1-specific GEF that locks Rab1 in the active GTP-bound state, promoting the recruitment of GOSR2 to the Legionella-containing vacuole (LCV). This recruitment is thought to facilitate the fusion of ER-derived vesicles with the LCV, providing membranes for the replication vacuole.

**Chlamydia trachomatis:** Chlamydia, an obligate intracellular pathogen, resides within a parasitophorous vacuole (inclusion) that intercepts host trafficking pathways. The chlamydial protease CPAF cleaves GOSR2, leading to its degradation. This cleavage disrupts Golgi trafficking and may contribute to the rerouting of nutrients to the inclusion.

### 5.3 Immune Evasion Mechanisms

GOSR2 has been implicated in the secretion of immune mediators, and pathogens may target GOSR2 to suppress immune responses:

- **Influenza A virus:** The viral NS1 protein binds to GOSR2 and inhibits the secretion of type I interferons (IFN-α/β). This suppression of IFN secretion allows the virus to evade the innate immune response.
- **Mycobacterium tuberculosis:** M. tuberculosis infection of macrophages leads to reduced GOSR2 expression, resulting in impaired secretion of pro-inflammatory cytokines (TNF-α, IL-6). The bacterial effector ESAT-6 has been shown to downregulate GOSR2 transcription via inhibition of the transcription factor SP1.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 GOSR2 as a Therapeutic Target

The dual role of GOSR2 in both genetic disease and cancer makes it an attractive but challenging therapeutic target. Strategies for modulating GOSR2 function include:

**For EPM6 (Loss-of-Function):**

- **Gene Therapy:** Adeno-associated virus (AAV) vectors encoding wild-type GOSR2 are in preclinical development. AAV9-GOSR2 has been shown to rescue Golgi trafficking defects in patient-derived fibroblasts and improve motor function in a GOSR2 knockout mouse model.
- **Readthrough Agents:** For nonsense mutations (e.g., p.Gln40Ter), aminoglycoside antibiotics (gentamicin, G418) and the investigational drug ataluren (PTC124) can promote readthrough of premature termination codons, producing full-length functional protein.
- **Antisense Oligonucleotides (ASOs):** For splice-site mutations, ASOs that modulate splicing to restore the reading frame are being explored.

**For Cancer (Gain-of-Function or Context-Dependent):**

- **Small-Molecule Inhibitors:** Compounds that inhibit GOSR2 function by blocking its interaction with STX5 are in early-stage development. A high-throughput screen identified the compound NSC-23766 as a GOSR2-STX5 interaction inhibitor, but its specificity and potency require optimization.
- **Proteolysis-Targeting Chimeras (PROTACs):** PROTACs that recruit E3 ligases to degrade GOSR2 are being developed for cancers where GOSR2 is overexpressed (e.g., HCC, PDAC).

### 6.2 Pharmacogenomic Considerations

GOSR2 genetic variants may influence drug response:

- **Chemotherapy Resistance:** The GOSR2 expression level predicts response

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)